Company Overview of Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation, through its subsidiaries, discovers, develops, manufactures, and markets human and animal health care products in the United States. It offers cardiovascular, respiratory, HIV, immunology, central nervous system, and urology products; active pharmaceutical ingredients; oral liquids, tablets, and capsules; and products for the treatment of diseases in dogs, cats, horses, cattle, and swine. The company also provides over-the-counter health care products, including Dulcolax, which is used for occasional constipation and irregularity problems; Zantac that is used for the prevention and relief of heartburn; and Mirapex ER, a tablet for the signs and symptoms of i...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1984
Key Executives for Boehringer Ingelheim Corporation
Chief Executive Officer, President and Managing Director
Chairman of the Board of Managing Directors
Compensation as of Fiscal Year 2017.
Boehringer Ingelheim Corporation Key Developments
Boehringer Ingelheim and Weill Cornell Medicine Sign COPD Research Deal
Feb 16 17
Boehringer Ingelheim is collaborating with Weill Cornell Medicine to identify new treatment approaches that could halt or even reverse lung tissue damage in coronary obstructive pulmonary disorder (COPD). The three-year collaboration will draw on Weill Cornell Medicine's Department of Genetic Medicine's unique understanding of chronic airway diseases and experience in the investigation of new therapeutic concepts for airway repair, alongside Boehringer Ingelheim's expertise in the discovery and development of novel therapies for respiratory diseases. This is the second collaboration between the two, having previously worked together in inflammatory bowel disease (IBD).
Boehringer Ingelheim Corporation Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017
Dec 20 16
Boehringer Ingelheim Corporation Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.
Boehringer Ingelheim Completes Enrollment for Pivotal Phase III Trial
Nov 10 15
Boehringer Ingelheim announced it has completed enrollment for the pivotal Phase III trial of BI695501, a biosimilar candidate to adalimumab. This announcement was made following recent results from a Phase I trial that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. These Phase I data for BI695501 were discussed at the American College of Rheumatology /Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in San Francisco. The Phase III clinical trial is a randomized, double-blind, parallel arm, multiple dose, active comparator trial in patients who have been diagnosed with moderate to severe rheumatoid arthritis and are currently being treated with methotrexate. Each participant is randomized to receive either BI695501 or the U.S.-licensed reference product every two weeks for 48 weeks.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|